Clinical trials often get talked about in terms of science, innovation, and new treatments, but the day-to-day reality is a lot more operational than most people realize. A trial can have a strong concept, serious funding, and experienced researchers behind it, yet still struggle because the right patients are hard to find at the right time.
That is the problem Josh Sabol set out to tackle with HealthKey. Instead of building another broad healthcare AI company with a vague promise to “transform” the industry, he focused on a specific bottleneck that research sites deal with every day. Clinical teams were losing time digging through records, missing potential matches, and falling behind on enrollment. HealthKey was built to make that process faster, sharper, and far more practical.
In a space where delays can slow research and limit patient access to new treatments, that focus matters. HealthKey’s story stands out because it is tied to a real operational pain point, and Josh Sabol’s approach seems rooted in execution rather than noise.
Who Is Josh Sabol and What Is HealthKey
Josh Sabol is the founder and CEO of HealthKey, a startup built around one clear idea: helping clinical trial teams identify eligible patients faster. Before launching the company, he worked in product roles, including time at AWS, and that background matters when you look at how HealthKey is positioned. The company is not framed as a theoretical research project. It is framed like a workflow product designed to solve a problem inside a complex system.
That matters because clinical research is full of friction. Research sites do not need abstract promises. They need tools that fit into the way coordinators, investigators, and operations teams already work. HealthKey steps into that gap by using AI to prescreen patients against trial eligibility criteria, helping research teams narrow down qualified candidates without spending endless hours on manual chart review.
The company has already drawn attention as part of Y Combinator’s Winter 2025 batch, which gave HealthKey early visibility and added credibility to its growth story. For a young healthcare startup, that milestone matters because it signals that the market sees potential in the problem it is solving and the way it is solving it.
The Problem HealthKey Was Built to Fix
Patient recruitment is one of the most stubborn challenges in clinical research. On paper, it sounds straightforward. Find patients who match a study’s inclusion and exclusion criteria, reach out to them, confirm eligibility, and move forward. In practice, it is slow, repetitive, and often messy.
A research coordinator may need to look through thousands of records to find a very small number of patients who actually qualify. Some criteria are easy to spot in structured data fields, but many are buried in clinical notes, scans, histories, lab results, or physician documentation. Native EHR search tools often help only at a broad level. They can pull up a large population with a general diagnosis, but they usually cannot do the detailed matching needed for a complex trial protocol.
That creates a costly chain reaction. Coordinators spend hours reviewing charts manually. Sites miss enrollment targets. Sponsors wait longer. Patients who might have been strong candidates never get identified in time. Even when teams know the right patients are likely somewhere inside their existing records, getting to them can feel painfully inefficient.
This is the environment Josh Sabol stepped into with HealthKey. Instead of treating patient identification like a side issue, he built the company around the idea that faster, more accurate screening can change the economics and pace of clinical research.
How Josh Sabol Built HealthKey Around Speed and Precision
The smart part of HealthKey’s positioning is that it does not try to remove humans from the process. That would be unrealistic in clinical research, where judgment, oversight, and evidence matter. Instead, the company sits earlier in the workflow and helps teams do the most time-consuming part faster.
HealthKey connects with a clinic’s electronic health record system and uses AI to compare a patient’s history against the detailed eligibility criteria of a clinical trial. That may sound simple when described in one sentence, but it solves a very real operational problem. Trial criteria are rarely limited to a single diagnosis code. They often include combinations of symptoms, measurements, time windows, treatment history, imaging details, and exclusion rules that are difficult to search at scale.
By handling both structured and unstructured clinical data, HealthKey aims to surface stronger candidate lists than older search methods. The platform also highlights supporting evidence for each potential match, which matters because research teams still need to verify whether a patient truly qualifies. In other words, the product is not just about speed. It is about speed with context.
That balance makes HealthKey more practical for clinical operations. A research coordinator does not want a giant list of loose possibilities. They want patients who are worth reviewing, along with the reason they were flagged. That makes the workflow easier to trust and easier to use.
From a founder perspective, this says a lot about Josh Sabol’s approach. He did not build HealthKey around a flashy AI narrative alone. He built it around a real user need inside a high-friction healthcare workflow.
Why This Matters to Clinical Trial Teams
When people outside the industry think about clinical trial problems, they often focus on the science. Inside the industry, though, operational bottlenecks can be just as important. If a site cannot find enough eligible patients, the trial slows down no matter how promising the treatment may be.
That is why HealthKey’s value proposition is easy to understand. Faster patient identification can lead to faster enrollment. Better matching can reduce wasted effort. Coordinators can spend less time buried in manual review and more time on outreach, follow-up, scheduling, and study execution.
There is also a broader patient impact. The longer it takes to identify trial candidates, the greater the chance that patients miss the eligibility window, start another treatment, or simply never hear about an option that could have been relevant to them. A stronger recruitment workflow does not just help sponsors and sites. It can also improve access to clinical research opportunities.
This is one reason HealthKey feels timely. AI in healthcare gets a lot of attention, but the tools that actually matter tend to be the ones that solve a specific operational problem in a measurable way. HealthKey is easier to understand because it is not trying to do everything. It is focused on one painful part of the clinical trial process and trying to do it well.
The Early Momentum Behind HealthKey
For an early-stage healthcare company, credibility matters. Health systems, research organizations, and clinical teams are not quick to adopt new tools unless they believe the product has real value. That is part of what makes HealthKey’s early momentum notable.
Its acceptance into Y Combinator’s Winter 2025 batch gave the company a visible early milestone. That does not guarantee long-term success, but it does show that experienced startup investors saw promise in the company’s direction. In a crowded AI market, that kind of early validation helps HealthKey stand out.
The company’s positioning also feels sharper than many early startups. It is not trying to be a general-purpose healthcare platform. It is focused on AI-powered patient identification for clinical trials. That specificity is useful. It gives the company a clearer message, a clearer buyer, and a clearer problem to solve.
Josh Sabol’s background in product and operations appears to show up in that focus. HealthKey is presented as something built for actual research-site workflows, not just for presentations or investor decks. That kind of discipline can be a real advantage in healthcare, where success often comes from solving a narrow problem exceptionally well.
A Real Example of HealthKey in Action
One of the strongest parts of the HealthKey story is that there is already a concrete example of the product being used in a real research setting. In a published case study, HealthKey described its work with Urology Centers of Alabama on a study involving eCoin for urgency urinary incontinence.
According to the case study, the research team was under pressure to meet its enrollment target but was dealing with the familiar recruitment challenge of searching through large volumes of records and notes for patients who matched very specific criteria. The difficulty was not just finding patients with the right general condition. It was identifying those who fit the full protocol while ruling out disqualifying factors.
HealthKey connected with the clinic’s Veradigm AllScripts EHR system, processed 22,000 patient records and 2.1 million data points, and returned a set of eligible patients within 24 hours. That kind of speed is important on its own, but the more meaningful part is what happened next. The case study says HealthKey identified 28 eligible patients, and within the following six weeks the site was able to meet its enrollment target.
That is the sort of example that helps explain why the company is getting attention. It moves the story away from startup language and into operational results. Instead of saying clinical trial AI should make things faster, HealthKey was able to point to a real-world setting where faster identification directly supported enrollment.
For a founder-led success story, this is where Josh Sabol’s work becomes easier to understand. The company is not gaining traction because it sounds futuristic. It is gaining traction because the workflow problem is real and the outcome is easy for the market to care about.
What Makes Josh Sabol’s Approach Worth Watching
A lot of startup founders talk about large markets. Fewer show that they understand where the daily friction actually lives. What makes Josh Sabol’s approach more interesting is that HealthKey is built around a problem that is specific, expensive, and repeatedly felt by research teams.
That gives the company a practical edge. Instead of selling a broad promise to “improve healthcare,” HealthKey is tied to a direct job to be done. Help research sites find the right patients faster. Help clinical operations teams reduce manual work. Help studies move forward with less delay.
That level of focus usually makes a company easier to build and easier to explain. It also gives the founder a stronger story. Josh Sabol is not simply attached to another startup in the healthcare AI category. He is attached to a company with a defined use case, a measurable pain point, and a product that fits a real operational workflow.
There is also something important in the way the company appears to frame AI. HealthKey is not presented as a replacement for clinical judgment. It is presented as a tool that helps research teams work through complexity faster. In healthcare, that distinction matters. Trust is earned more easily when the tool supports experts rather than pretending to remove them.
How HealthKey Fits Into the Bigger Clinical Trial Shift
Clinical trial operations are under pressure from multiple directions at once. Protocols are often complex. Recruitment timelines are demanding. Sites are expected to move quickly while handling limited staff capacity. On top of that, much of the information needed to identify eligible patients sits across structured fields, physician notes, past encounters, and supporting documentation.
That makes patient identification a natural area for AI-assisted improvement. It is repetitive enough to benefit from automation, but nuanced enough that teams still need evidence and oversight. That is exactly the kind of environment where a focused workflow product can create value.
HealthKey fits into this shift by aiming to make clinical trial screening more scalable without making it feel disconnected from how research teams actually work. That is part of why the company has a believable growth story. It is not asking the market to accept a radical new behavior. It is helping existing teams do something they already need to do, only faster and with more precision.
If that approach continues to work, HealthKey could become part of a larger change in how research sites think about enrollment. Instead of treating recruitment as a largely manual function supported by limited search tools, more organizations may start expecting AI-assisted screening as a practical part of clinical operations.
Why the HealthKey Story Is Gaining Attention
The success angle around Josh Sabol and HealthKey is not built on hype alone. It comes from the way the company connects a founder, a product, and a clear market pain point. The story is easy to follow. Clinical trial teams struggle to find eligible patients. Manual review slows enrollment. HealthKey uses AI to help research sites identify likely candidates faster. Early traction and case-study results make that promise more credible.
That is why the company is becoming a name worth watching in clinical trial AI. It speaks to a real need inside healthcare operations, and it does so in language that decision-makers can understand. The promise is not abstract. It is tied to time saved, candidates identified, enrollment targets met, and workflows improved.
For Josh Sabol, that makes the founder story more compelling. He is not just building in a hot market. He is building around a problem that clearly matters to research coordinators, principal investigators, sponsors, and patients alike. In a healthcare environment where execution matters more than buzzwords, that is a strong foundation to build on.
